Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

AEP331

Prev Next
Section Contents Cite
Endocrine Abstracts (2020) 70 AEP331 | DOI: 10.1530/endoabs.70.AEP331

ECE2020 Audio ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (285 abstracts)

Clinical and metabolic benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapy in diabetic patients with psychiatric comorbidities

María Concepción Terroba-Larumbe 1 , Cristina Crespo-Soto 1 , Jose Maria Palacio-Mures 1 , Manuel Gonzalez-Sagrado 2 , Rosa Conde-Vicente 2 , Marta Ventosa-Viña 1 , Silvia Peña-Lozano 1 , Ainara Portela-Martin 1 , Marta Fernandez-Nuñez 3 , Mar Calleja-Barnada 1 & Luis Cuellar-Olmedo 1

0
Err

1Hospital Rio Hortega, Endocrinologia y Nutricion, Valladolid, Spain; 2Hospital Rio Hortega, Unidad de apoyo a investigacion, Valladolid, Spain; 3Hospital Rio Hortega, Oftalmologia, Valladolid, Spain

Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapyhas proven effective in type 2 diabetes but there is little data on its effect in patients with psychiatric comorbidity, who usually present worse metabolic and clinical control. The aim of this study was to evaluate if there are differences in the effect of this therapy in relation to the presence of these pathologies.

Methods: 225 patients included in a therapy protocol with SGLT2i, 54.9% men, mean age 63.7 ± 10.0, time of evolution of diabetes 11.1 ± 9.0 years, were evaluated analyzing the changes in clinical and biochemical parameters at baseline and after one year of therapy with SGLT2i. The analysis was performed in the global and separating in two groups according to the presence of psychiatric comorbidity. Quantitative variables are expressed by mean (standard deviations). Qualitative variables are expressed by frequencies and percentages. Paired samples T-test are used in the statistical analysis. We consider significant P < 0.05.

Results: 24.4% of patients presented psychiatric comorbidities, and the most frequent diagnoses were anxiety (34.5%), depression (32.7%) and anxiety-depressive syndrome (16.4%). Baseline data and after follow-up expressed as means (s.d.) and means difference (s.d.) (95% CI): weight (kg) 91.2 ± 19.7 vs 87.9 ± 19.1; 3.4 ± 5.1 (2.6 to 4.2) (P < 0.001), body mass index (kg/m2) 34.5 ± 6.2 vs 33.3 ± 6.1; 1.2 ± 2.1 (0.9 to 1.6) (P < 0.001), glycated hemoglobin (%) 8.2 ± 1.2 vs 7.4 ± 1.1; 0.7 ± 1.2 (0.5 to 0.9) (P < 0.001), glucose (mg/dl) 169.6 ± 69.3 vs 143.5 ± 46.3; 26.2 ± 73.5 (14.7 to 37.6) (P < 0.001), systolic blood pressure (mmHg) 149.9 ± 17.8 vs 144.0 ± 18.8; 5.9 ± 20.2 (2.5 to 9.3) (P = 0.001), diastolic blood pressure (mmHg) 84.0 ± 11.3 vs 82.0 ± 10.7; 2.0 ± 10.2 (0.3 to 3.7) (P = 0.024), high-density-lipoprotein cholesterol (mg/dl) 45.3 ± 11.9 vs 48.8 ± 13.7; 3.5 ± 11.4 (5.3 to 1.6) (P < 0.001), triglycerides (mg/dl) 189.0 ± 102.5 vs 160.7 ± 77.8; 28.4 ± 94.0 (13.6 to 43.1) (P < 0.001), glomerular filtration rate (ml/min/1.73 m2) 82.6 ± 34.0 vs 88.2 ± 24.5; 5.6 ± 26.8 (9.9 to 1.3) (P = 0.01). There were no significant changes in total cholesterol, low-density-lipoprotein cholesterol and albuminuria. In the separate analysis we found no significant differences regarding the benefit in patients who had psychiatric comorbidity.

Conclusions: Psychiatric comorbidity in diabetic patients is associated with worse results of some pharmacological treatments, probably due to a loweradherence to changes in lifestyle. In our study, SGLT2i therapyoffers the same advantages in terms of metabolic and clinical control in this group of patients

Volume 70

Prev Next

22nd European Congress of Endocrinology

Online
05 Sep 2020 - 09 Sep 2020

European Society of Endocrinology 

Browse other volumes

Summary Abstracts Abstract Book Volume Editors

Article tools

| Disclaimer

My recent searches

No recent searches.

My recently viewed abstracts

Clinical and metabolic benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapy in diabetic patients with psychiatric comorbidities (<1 min ago)

Authors

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more